Press Releases

Oncopeptides Welcomes New Board Member – Luigi Costa

August 15, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors.

Read more

Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016

July 7, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with rel...

Read more

Oncopeptides prepare for pivotal Phase 3 clinical trials

April 30, 2016 - Other press release

Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical trials...

Read more

Oncopeptides have a successful meeting with MHRA

March 31, 2016 - Other press release

Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients.

Read more

Oncopeptides CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

January 13, 2016 - Other press release

Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

Read more